黑色素瘤脑转移的立体定向放射外科与免疫治疗:治疗模式与治疗结局
基于美国国家癌症数据库2011至2013年1104例黑色素瘤脑转移患者,其中912例仅接受放疗、192例接受放疗联合免疫治疗。放疗联合免疫治疗组中位总生存为11.1个月,优于仅放疗组的6.2个月(P<0.001),倾向性评分匹配后仍显著。免疫治疗使用率从12.9%升至22.8%。
要点
- 放疗联合免疫治疗组中位总生存11.1个月,优于仅放疗组的6.2个月(P<0.001)。
- 合并颅外疾病(OR 1.603)及接受立体定向放射外科(OR 1.955)者更可能接受免疫治疗。
- 免疫治疗使用率从2011年12.9%升至2013年22.8%,但绝大多数患者仍未接受免疫治疗。
核心结论
- 放疗联合免疫治疗与黑色素瘤脑转移患者总生存改善相关。
- 作者认为鉴于本分析固有的选择偏倚,需开展前瞻性试验研究放疗(尤其立体定向放射外科)联合免疫治疗。
研究设计与样本
- 回顾性分析美国国家癌症数据库2011至2013年黑色素瘤脑转移患者。
- 排除无法确定转移部位及未接受放疗的患者后,共纳入1104例:912例仅放疗,192例放疗联合免疫治疗。
- 采用Cox模型进行单变量和多变量分析确定总生存预测因素,Kaplan-Meier法比较总生存,逻辑回归模型确定免疫治疗使用预测因素,并用倾向性评分分析基线特征差异。
- 显著性定义为P值≤0.05。
- 中位随访时间6.4(0.1-56.8)个月。
主要发现
- 合并颅外疾病者接受免疫治疗的可能性更高(OR 1.603,95%CI 1.146-2.243,P=0.006)。
- 接受立体定向放射外科者较全脑放疗者接受免疫治疗的可能性更高(OR 1.955,95%CI 1.410-2.711,P<0.001)。
- 免疫治疗使用率在2011至2013年间从12.9%升至22.8%。
- 多变量分析中与更优总生存相关的因素包括较年轻年龄、较少合并症、无颅外疾病、接受免疫治疗及立体定向放射外科。
- 放疗联合免疫治疗组中位总生存11.1(95%CI 8.9-13.4)个月,仅放疗组为6.2(95%CI 5.6-6.8)个月(P<0.001),倾向性评分匹配后仍显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出本分析存在固有的选择偏倚。
- 作者认为需开展前瞻性试验研究放疗(尤其立体定向放射外科)联合免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preclinical studies have suggested that radiation therapy (RT) enhances antitumor immune response and can act synergistically when administered with immunotherapy. However, this effect in melanoma brain metastasis is not well studied. We aim to explore the clinical effect of combining RT and immunotherapy in patients with melanoma brain metastasis (MBM). MATERIALS AND METHODS: Patients with MBM between 2011 and 2013 were obtained from the National Cancer Database. Patients who did not have identifiable sites of metastasis and who did not receive RT for the treatment of their MBM were excluded. Patients were separated into cohorts that received immunotherapy versus patients who did not. Univariable and multivariable analyses were performed using Cox model to determine predictors of OS. Kaplan-Meier method was used to compare OS. Univariable and multivariable analyses using logistic regression model were used to determine the factors predictive for the use of immunotherapy. Propensity score analysis was used to account for differences in baseline patient characteristics between the RT and RT + immunotherapy groups. Significance was defined as a P value ≤ 0.05. RESULTS: A total of 1104 patients were identified: 912 received RT alone and 192 received RT plus immunotherapy. The median follow-up time was 6.4 (0.1-56.8) months. Patients with extracranial disease (OR 1.603, 95% CI 1.146-2.243, P = 0.006), and patients receiving SRS (OR 1.955, 95% CI 1.410-2.711, P < 0.001) as compared to WBRT, had a higher likelihood of being treated with immunotherapy. The utilization of immunotherapy had nearly doubled between 2011 and 2013 (12.9-22.8%). On multivariable analysis, factors associated with superior OS were younger age, lower medical comorbidities, lack of extracranial disease, and treatment with immunotherapy and SRS. The median OS was 11.1 (8.9-13.4) months in RT plus immunotherapy vs. 6.2 (5.6-6.8) months in RT alone (P < 0.001), which remained significant after propensity score matching. CONCLUSIONS: An increase in trend for the use of immunotherapy was noted, however, an overwhelming majority of the patients with this disease are still treated without immunotherapy. Addition of immunotherapy to RT is associated with improved OS in MBM. Given the selection biases that are inherent in this analysis, prospective trials investigating the combination of RT, especially SRS and immunotherapy are warranted.
引用
- Gabani P, Fischer-Valuck BW, Johanns TM, et al. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes. Radiother Oncol. 2018. PMID: 29960685. doi:10.1016/j.radonc.2018.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。